ccording to facts and figures provided by the American Diabetes Association, there are an estimated 15.7 million people in the United States with diabetes. Approximately 5.4 million of these people have not yet been diagnosed. 1 The hy perg lyc emia resulting from types I and II diabetes mellitus can lead to multiple challenges for the person with diabetes. Patients who are struggling to compensate for a lack of insulin secretion and/or a lack of insu lin efficiency face p o ssibl e com p licat io ns, such as retinopathy, nephropathy, neuropathy, and atherosc lerosis. At the core of preventing and dealing with diabetes mellitus is an understanding of how the body regulates the metabolism of its principal energy source, glucose, and how specific nutrients, diet modifications, and supportive botanical medic ines can be utilized to optimize glucose metabolism.
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Specific Nutrients for Glucose Metabolism

Chromium
Trivalent chromium is one of the most studied nutrients in glucose metabolism. In one study that highlights the need for chromium supplementation in patients with type II diabetes, resea rchers compared fasting blood and second-morning urine samples between 93 patients with type II diabetes and 33 healthy controls.
The researchers found that mean serum chromium levels were approximately 33 p ercent lo w er a nd urine lev els we re almost 100 percent higher in the patients with diabetes vers us the controls. 2 In add ition, while su bjects who did not have diabetes showed a negative correlation between fasting levels of plasma chromium and insulin, no such correlatio n existed in t he subject s with diabe te s. M o r eo v er , t he aut ho rs no t ed , based on their work over several years, that, in the early stages of diabetes, an inverse rela tionsh ip betw een plasma chromium and glucose levels has been o b s e r v e d , w h i c h d i sa p p e a rs af t e r 2 y e a r s . T h e a u t h o r s s u g g e s t e d t h a t chromium loss over years may worsen an already existing chromium deficiency in p atients wit h typ e II dia betes and contribute to their insulin resistance.
In a recent review, 3 more than a dozen clinical trials in patients with type II diabetes have shown positive results from supplement ation with chromium. The m u l t i p l e b e n e f i t s r e p o r t e d i n c l u d e improved fasting glucose, improved glucose tolerance, decreased insulin levels 60 minutes after eating, decreased glycosylated hemoglobin levels, and an increase in high-density lipoprotein (HDL). These m et abo li c im p ro ve me nt s se em t o be caused by several mechanisms, including an incr ease in t he num ber o f i nsulin receptors in insulin-dependent cells, such as adipocytes and hepatocytes, and an increase in phosphorylation of the insulin receptor, which results in increased sensitivity of receptors to insulin.
With regard to this second mechanism of action, an increased phosphorylation of insulin receptors, there is now some elucidation of how chromium might act at a very basic molecular level. According to o n e re ce nt l y p ro p o se d m o de l , 4 fo ur chromium ions are needed to bind to a low-molecular-weight oligopeptide so t h a t t h e r e s u l t i n g c o m p l e x o f t h e oligopeptide and chromium can assume the correct geometrical shape needed to bind to the phosphorylating portion of the insulin receptor. A potentially important sugge stion ma de in thi s model is that, in order for the bioactive form of chromium picolinate to release its chromium ion to enter a cell, the chromium must first undergo a reduction reaction, which may generate hydroxyl radicals. Perhaps, in the future, it will be most efficient to give patients who take chromium adjuvant antioxidant support.
While there are occasional studies that do not report benefits of chromium supplementation in glucose metabolism, 5 t hese s tudie s t yp ically us e a do se of chromium that is less than 200 µg/day or use a form of chromium, such as chromium chloride, which seems not to be as bioavailable as chromium picolinate. A reasonable dosage range for chromium supplementation, suggested in the literature, would be 200-1000 µg/day, with greater benefit expected from the dose larger dose. It is also important to educate patients about research demonstrati n g t h a t s i m p l e s u g a r c o n s u m p t i o n i n c r e a s e s t h e a m o u n t o f c h r o m i u m excreted in the urine. 6 
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Vanadium Vanadium, which is positioned next to chromium as a transition metal on the periodic table, has also been studied for its effects on glucose metabolism. In one recently published study of subjects who received 150 mg per day or 300 mg per day of vanadyl sulfate for 6 weeks, there was improvement in three of five subjects who received 150 mg and in four of eight of the subjects who received 300 mg. 7 Reductions in fasting glucose and glycosylated hemoglobin were enough to be significant, although not dramatically so. In addition, this work demonstrated that, i n s k e l e t a l m u s c l e , v a n a d i u m a l s o a p p e ar s t o m o d ul a t e t h e n um b e r o f insulin receptors and their phosphorylat i o n . T w o o t h e r s m a l l s t u d i e s a l s o demonstrated improvement in glycemic c o n t r o l u s i n g o n l y 1 0 0 m g / d a y * o f vanadyl sulfate for 3 or 4 weeks, and, in both studies, the improvement in blood glucose control continued for periods of 2 or 4 weeks after supplem entation had ended. 8, 9 It is important to note that that even the lower doses of vanadyl sulfate (100 mg per day) caused some gastrointestinal intolerance (see chart entit led Key Nutrients for Controlling Glucose Metabolism.
A different, organic form of vanadium, bis(maltolato)oxovanadium (BMOV), has also been shown to be effective in lowering glucose levels, at least in rat models. The dosage of BMOV needed, however, to lower glucose levels effectively, was only half of the dose of vanadyl sulfate required to obtain the same effect.
B Vitamins
T h e w a t e r -s o l ub l e B v i t a m i n s a r e r e q u i r e d c o f a c t o r s f o r m a n y o f t h e enzymes required for metabolizing glucose via glycolysis and the Kreb's cycle, and a growing body of literature suggests their importance in diabetes. For examp le, in the case o f vitamin B 6 , a study of the serum levels of 518 patients with diabetes reve aled that pyrido xal levels were significantly lo wer co mpared to levels in 371 controls, with 25 percent o f t he p atients with diabet es having levels below the lower limit of the norm al range . 10 In anothe r study co mp aring 50 p ati ents w ith diabet ic ne uropathy to patients with dia betes but without without neuropathy, serum p y r i d o x al le v el s w e r e s i g ni f i ca n t l y lower in the patients with diabetic neuropathy. 11 There are also several studies demonstrating the clinical effects of B vitamins supplementation on diabetes. One study of 24 patients with diabetic neuropathy utilized a treatment with a complex of vitamins B 6 , B 12 , and a form of B 1 modified to be more lipid soluble. After 12 weeks, there was significant improvement in the nerve conduction velocity of the peroneal nerve and a trend toward improvement in the thresh old level of vibration perception. 12 One informative study of a B vitamin in di abe t es re se arch w as do ne s o me years ago by re searchers w ho to ok a small group of patients with type I diabet es o ff insulin treat ment and gave them either 16 mg/da y of biot in or a p l ac eb o . 1 3 C o m p a re d t o t he co n t ro l group, the mean blood glucose level of the biotin-treated group was significantly lower after 1 week of treatment (126 mg per dL in the biotin group versus 266 m g p e r d L i n t h e co n t r o l g r o u p ) . I n ex am ining the lev els o f t issue biot in c o m p a r e d t o p l a s m a b i o t i n a m o n g patients with type I diabetes and controls without diabetes, it was found that an inc reasin g ra tio of tissue biotin to p l a s m a b i o t i n w a s a s s o c i a t e d w i t h increasing fasting blood sugar levels in the subjects with diabetes, but not in subjects without the disorde r. Perhaps future work will hel p to confirm that biotin can control blood glucose levels and elu cidate the differences in ho w biotin is utilized in people with or without diabetes.
N iacinam ide is also worth sp ecific ment ion because it has been shown to help prevent type I diabetes in laboratory animals. These o bservatio ns ha v e been noted in at least ten clinical trials of which six were double-blinded . These studies involved patients with type I diabetes who had been diagnosed with the namide. Other positive findings included p ro longed rem issions, low er insulin requirements, increased beta-cell funct i o n , a n d e n h a n c e d m e t a b o l i c c o ntrol. 14,15
Caveat
ak e n w i t h t h e objective of reducing hyperglycemia significantly, it is impo rtant to mo ni to r blood glucose levels adequately in order to avoid severe hypoglycemia durin g treatment. See box entitled Key Nutrients for Controlling Glucose Metabolism for more detailed caveats.
Dietary Interventions in Diabetes Mellitus
Dietary modifications can be a powerful tool for preventing and treating diab e t e s . I f , fo r e x am p l e , a cl i n i ci a n i s treating a patient who is at a high risk of developing type II diabetes before symptoms of hyperinsulinemia and/or hyperg l y c e m i a b e c o m e a c u t e , t h i s i s a n excellent opportunity to emphasize the potential benefit of cereal fiber. In a large prospective study of 65,173 females over 6 years, researchers looked for associations between the glycemic index of subjects' diets and their risk of developing type II diabetes. 16 A glycemic index is an indic ation of a food's potential to raise blood glucose and the demand the food crea tes for insu lin . Foods with a hig h glycemic index generally include items such as white bread, mashed potatoes, w hi te rice, and cola beverages. Mo re intermediate-range glycemic foods are items such as apples and orange juice. Low-glycemic foods are generally those that maintain their natural unprocessed fibers, such as broccoli and peanut butter.
In this prospective study, women in the qu in tile with the high est avera ge glycemic index had a significantly higher risk of developing type II diabetes (Relative risk [RR], 0.72; confidence interva l [CI], 0.58-0.90; P = 0.001) compared to w o m e n w i t h t h e l o w e s t a v e r a g e glycemic ind ex. One o f the strongest associations for an individual food type was seen in the analysis of cereal fiber intakes and the risk for developing diabetes. Women in the study quintile with the highes t media n cereal fiber intake ( 7 . 5 g / d a y ) h a d a n R R o f 0 . 7 2 ( C I , 0.58-0.90; P = 0.001) of developing type II diabetes compared to the women in th e q uint i le wi t h t he lo w es t m e dia n intake of cereal fiber (2.0 g/day). In contrast, women with a diet characterized by a high glycemic load and a low cereal f i b e r i n t a k e h a d a n R R o f 2 . 5 0 ( C I , 1.14-5.51) for developing type II diabetes compared to women eating a diet with a low glycemic load and high cereal fiber. Results from the same research team follo wing a sample o f more than 42,000 men prospectively were similar. 17 An additional association in this work that was significant was the risk of diab et e s an d m a gn es ium in ta ke . In t h e women's study, subjects with a median intake of 338 mg/day had an RR of 0.62 (CI, 0.58-0.90; P <0.001) compared to w o me n w it h a m ed ia n in ta ke o f 22 2 mg/day. This is especially important to keep in mind because a lack of sufficient m agnesium is so e as ily rem edied by magnes ium supplementation. In fact, although supplementation did not seem to improve glycemic control in subjects who were already diagnosed with type II diabetes, ther e is rese arch showin g that magnesium levels tend to be low in There is research showing that magnesium levels tend to be low in subjects with diabetes and that 3 months of supplementation is adequate for reversing the problem. subjects with diabetes and that 3 months o f s up p l e m e n t at io n i s a de q u at e fo r reversing the problem. 18 One form of fiber that may be particularly useful for treating patients once they are diagnosed with either type I or type II diabetes is the fiber from legumes. In one study of 9 patients with type I diabetes and 18 with typ e II dia betes, subjec ts were placed for 6 weeks on a high carbohydrate diet that was rich in legumes and then also a low-carbohydrate diet for 6 weeks. 19 In subjects with diabetes o f either types, the mean preprandial and 2-hour postprandial blood glucose levels were signific antly lower when the subjects were on the diet that was rich in legumes. The amount of glucose passed in the subjects' urine was also significantl y l e ss w he n t he y w e r e o n t h e h ig hlegume diet.
Select Botanical Considerations for Treating Diabetes
An additional consideration in the diet of patients with diabetes is the amount of protein they consume in relation to the health of their kidneys. One commonly referred to hypothesis suggests that too much protein intake causes hyperfiltration and glomerular hypertension, which leads to reduced kid ney function and eventual nephropathy in some patients with diabetes. 20 Clinical data that seem to support this hypothesis come from trials that have utilized limited protein intake and have shown subsequent, significant drops in glomerular filtration rate (GFR) and/or the amount of albumin excretion in subjects with diabetes. 21, 22 The complete rel ationsh ip between protein consumption and kidney health in patients who have diabetes is a complex one and is beyond the scope of this ar t ic le . O ne i nt e re st i ng h yp o t he si s, however, is that, while some forms of protein, especially beef, increase postprand ia l renal plasma flow and GFR, soy does not seem to alter postprandial renal function, suggesting that substituting soy for animal protein might protect patients who have diabetes from nephrop athy. 23 Unfortunately, a small pilot study designed to test this hypothesis, in which 8 men with type II diab e t e s r e p la c e d h a l f o f t h e i r p r o t ei n intake with soy protein, failed to show reduction in proteinuria. However, the study is important because it helps us to consider the concept that effects of protein intake on kidney health in patients with diabetes may be dependent on the type of protein being consumed. While w e a re s t il l a l o ng w a y fr o m un d erstanding the perf ec t diet for patients wi th di abet es, underst andi ng w hich t y p e s o f p r o t e i n s w i l l s p ar e k i d n ey fu n ct i o n mo s t e ff e ct i v e l y, a nd t h us delay the onset of nephropathy, could certainly be a fruitful field for future research.
Botanicals for Diabetes
The many botanicals useful in the treatment of diabetes could themselves occup y a le ng t hy re vi e w . H e re a fe w a re discussed briefly.
Pterocarpus
Rich in the flavanoid (-)-epicatechin, pterocarpus (Pterocarpus marsupium), an A yur v ed ic h er b, m ay be he lp f ul fo r patients with bo th typ e I and type II d i a b e t e s . I n a n a n i m a l s t u d y , r a t s w h o s e b e t a -i s l e t c e l l s w e r e f i r s t destroye d with the to xin alloxan and then giv en large intravenous doses of (-)-epicatechin experienced a return of normal blood glucose levels . 24 Histologic examination of pancreas samples sh owed rege ner ation of the beta-isle t cells. In a human trial in India, among su bjects who had been recen tly diagnosed w ith t ype II diabetes, 67 of 97 patients studied were able to control blood glucose levels (measured both for fasting and postprandial levels) after 12 weeks of treatment . Doses need ed for control ranged between 2-4 g of extract a n d t h e r e w e r e n o s i d e -e f f e c t s reported. 25 
Fenugreek
In a study of patients with type I diabetes given 50 g of defatted fenugreek (Trigonella foenumgracum) seed powder with both lunch and dinner for 10 days, there was a 54 percent decrease in 24-hour urine glucose excretion. Other bene f i t s f r o m t h i s h i g h s o u r c e o f f i b e r included decreases in total serum cholest e r o l , l o w -d e n s i t y l i p o p r o t e i n, a n d very-low-density cholesterol and triglyceride s, while levels of HDL remained unchanged. 26 
Bitter Melon
In a small study of nine patients with type II diabetes, a simple water extract of the fruit of bitter melon (Momordica charantia) was enough to lower blood glucose levels signif icantly during a 50-g oral glucose tolerance test. This improvement was not associated with an increase in serum insulin. 27 
Gymnema
A simple water extract from the leaf of gymnema (Gymnema sylvestre) may hold promise for p atients who ha ve eithe r type I or type II diabetes. Twenty-seven s u b j e c t s w i t h t y p e I d i a b e t e s w h o received 400 mg of such an extract per day showed a reduction in the need for insu lin as well as decreases in fasting b l o o d g l u c o s e a n d g l y c o s y l a t e d he moglobin and glyc osyl ated plasma protein levels. 28 When a water extract was given to 22 patients with type II diabe t e s f o r 18-20 m o nt h s , t he re w e re , again, significant decreases in the same b i o m a r k e r s u s e d i n t h e s t u d y w i t h patients who have type I diabetes. 29 One promising aspect of the study with subjects who have type II diabetes is that the extract was given safely in conjunction with other conventional medications that the subjects were already using. Five of the 22 subjects were able to discontinue their use of convent ional medications and manage their conditions solely with the gymnema extract. What is more, the reduction of insulin needs in the type I diabetes study combined with an observation of higher insulin levels in the type II diabetes study suggest that this extract is stimulating or even regenerating for beta-islet cells.
Corosolic Acid
Corosolic acid (Lagerstroemia speciosa), a plant extract, ha s been shown to he lp maintain normal transport of involved 12 p at ients with typ e II diabet es. W he n giv en 48 mg of G lucos ol, ™ (Soft G el Technologies, Inc., Los Angeles, California) these subjects experienced improved glucose metabolism. †,30,31 Although larger clinical trials are needed , the initial results have proven promising. Clinically, I have noted meaningful results often in patients with type II diabetes that have not responded fully to other approaches.
Conclusions
There is still much to learn about maximizing the benefits of nutrient supplem e n t a t i o n , d i e t m o d i f i c a t i o n , a n d botanical medicines in preventing and treating diabetes. What information is a v ai l ab l e, h o w e v e r, p r o v i d es m a n y poten tial complementary approache s that are worth trying to enable patients with this diso rder to live longer and healthier lives.
